ENहिन्दी soon

What the GLP‑1 trials found

Pick a medicine sold in India and a dose to see its main trial as the label reports it: average weight change, how many people reached 5, 10, 15 or 20%, and the side effects and stopping rates beside them.

Nothing you enter leaves your device Every number cites its label section
Trial averages, not a prediction for you. This doesn't replace the label or your doctor. Some people lose much more than the average and some lose very little. Talk to a qualified doctor before starting, stopping or changing a medicine.Information only, not a promotion. Every medicine named here is prescription-only. Only a doctor can decide whether one is right for you and prescribe it. We don't recommend, rank or favour any medicine. Where we list several, they're in alphabetical order. We don't sell medicines or take money from drug companies.

Pick a medicine and dose

Medicine
kg

Shows what the trial's averages and proportions would mean in kilograms. Not a prediction.

How these trials work
  • People were put into groups by chance: one got the medicine, one got a placebo (a dummy injection or dummy pill with no medicine in it).
  • Both groups got the same diet and activity advice.
  • The gap between the two groups is what the medicine added.
These trials can't be ranked against each other. They had different people, lengths, doses and diet advice, and ran at different times. Only a head-to-head trial tests two medicines in the same trial: see Compare.

Private by design: worked out in your browser. Nothing is sent or stored, and nothing goes in the link. Privacy notice

How this works

For each medicine we use the main trial reported in its label (prescribing information). India's pack inserts for these medicines are approved by CDSCO but aren't published online, so we use the US labels, which report each trial in full: section 14 ("Clinical studies") for weight, and section 6.1 for side effects and stopping rates, which often pools several trials; the card says which. Where the label doesn't give a number for that trial alone, we use the published trial paper and say so. Every number sits in one data block on this page with its source.

CDSCO expert-committee minutes show India's Wegovy, Poviztra, Ozempic and Rybelsus inserts are updated in line with the EU label.13 The EU label reports the same trials, sometimes with a different analysis. Each card says what the EU label gives: the same STEP 1 and PIONEER 1 figures, but different figures for SUSTAIN 1, SURMOUNT-1 and SURPASS-1, because it counts the data differently.

The trials are the same worldwide, so the results don't depend on where the medicine is sold. Only medicines sold in India are shown.8 Poviztra is the same semaglutide as Wegovy, and Yurpeak the same tirzepatide as Mounjaro. In India, Mounjaro is approved for weight and for type 2 diabetes, so it has a card for each: the weight trial comes from the US label for tirzepatide for weight (sold in the US as Zepbound).

"Mean" weight change is the average for the whole group. The share who reached at least 5, 10, 15 or 20% shows the spread: it's a range, not one number. If you enter your weight, we multiply it by the same percentages. That's arithmetic on trial averages, not a forecast.

Ozempic and Rybelsus are approved in India for type 2 diabetes, not weight loss. For them, and for Mounjaro's diabetes trial, the labels report weight change in kilograms only, so we show that and nothing more.

What this can't tell you

  • How much you will lose. Your result depends on you, your dose and how long you take it, and isn't predicted by a trial average.
  • Which medicine works more. Separate trials can't be ranked.
  • How results differ in Indian people. These trials enrolled people from many countries; few were from India.
  • What happens after stopping. Weight usually comes back in part: see Stopping and the long term.
  • Rare or long-term risks. Those are in each label's warnings, and in Side effects and risks.

Questions people ask

Can I compare the numbers for different medicines?

No. Each trial had different people, lengths, doses and diet advice, so the numbers can't be ranked against each other. Only a head-to-head trial, where both medicines are tested in the same trial, can compare them.

Is this how much weight I will lose?

No. These are trial averages, not a prediction for you. In every trial some people lost much more than the average and some lost very little. That's why the tool shows how many people reached each amount, not one number.

What is a placebo?

A dummy injection or dummy pill with no medicine in it. In these trials people were put into groups by chance, and both groups got the same diet and activity advice. The gap between the medicine group and the dummy group is what the medicine added.

Why are Ozempic and Rybelsus shown differently?

They're approved in India for type 2 diabetes, not weight loss. Their labels report weight change from diabetes trials in kilograms, and not how many people lost 5% or more, so the tool shows only the average change for them. Mounjaro's diabetes trial is shown the same way.

Which label do these numbers come from?

India's pack inserts for these medicines are approved by CDSCO but aren't published online, so we can't quote them. The trials are the same everywhere, and the US labels report them in full, with side-effect tables for each dose. CDSCO records show the Novo Nordisk inserts (Wegovy, Poviztra, Ozempic, Rybelsus) follow the EU label, so each card also says what the EU label reports. For Wegovy and Rybelsus it gives the same figures; for Ozempic and Mounjaro it uses a different analysis, and the card gives its figures too.13

Is anything I enter saved or sent?

No. The weight you enter is used only in your browser to turn the trial percentages into kilograms. Nothing is sent or stored.

Sources

  1. Wegovy (semaglutide) injection, US prescribing information, Novo Nordisk, revised 06/2026. Section 14.2 (Table 8: Study 2 = STEP 1; stopping rates in the Results text) and 6.1 (Table 3). Used for Wegovy and Poviztra. Maker's PDF · DailyMed. Checked 14 Oct 2026.
  2. Zepbound (tirzepatide) injection, US prescribing information, Eli Lilly, revised 08/2026. The US label for tirzepatide for weight. Section 14.1 (Table 2: Study 1 = SURMOUNT-1) and 6.1 (Table 1, Studies 1 and 2 pooled). Used for Mounjaro and Yurpeak for weight. Maker's PDF · DailyMed. Checked 14 Oct 2026.
  3. Mounjaro (tirzepatide) injection, US prescribing information, Eli Lilly, revised 08/2026. Section 14.2 (Table 4: SURPASS-1) and 6.1 (Table 1, SURPASS-1 and -5 pooled, and gastrointestinal text). Maker's PDF · DailyMed. Checked 14 Oct 2026.
  4. Ozempic (semaglutide) injection, US prescribing information, Novo Nordisk, revised 05/2026. Section 14.1 (monotherapy trial NCT02054897 = SUSTAIN 1, Table 3 and text) and 6.1 (Table 1 and gastrointestinal text). Maker's PDF · DailyMed. Checked 14 Oct 2026.
  5. Rybelsus (semaglutide) tablets, US prescribing information, Novo Nordisk, revised 1/2026. Section 14.2 (Trial 1 = PIONEER 1, NCT02906930, text under Table 4) and 6.1 (Table 2 and gastrointestinal text). Maker's PDF · DailyMed. Checked 14 Oct 2026.
  6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. PMID 35658024. Abstract: stopping because of adverse events 4.3%, 7.1%, 6.2% and 2.6%. Funded by Eli Lilly. PubMed. Checked 14 Oct 2026.
  7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. PMID 33567185. Funded by Novo Nordisk. PubMed. Checked 14 Oct 2026.
  8. GLP Guidebook. GLP‑1 cost calculator (India): which GLP‑1 medicines and strengths are sold in India, checked 11 Oct 2026.
  9. Wegovy (semaglutide), EU product information (summary of product characteristics), Novo Nordisk, European Medicines Agency. Section 5.1 (Table 4: STEP 1) and 4.8. India's Wegovy and Poviztra insert follows this label. EMA product information (PDF). Downloaded and checked 14 Oct 2026.
  10. Mounjaro (tirzepatide), EU product information, Eli Lilly, European Medicines Agency. Section 5.1 (Table 8: SURMOUNT-1; Table 2: SURPASS-1, on-treatment data without rescue therapy). EMA product information (PDF). Downloaded and checked 14 Oct 2026.
  11. Ozempic (semaglutide), EU product information, Novo Nordisk, European Medicines Agency. Section 5.1 (Table 2: SUSTAIN 1). India's Ozempic insert follows this label. EMA product information (PDF). Downloaded and checked 14 Oct 2026.
  12. Rybelsus (semaglutide), EU product information, Novo Nordisk, European Medicines Agency. Section 5.1 (Table 2: PIONEER 1, 7 and 14 mg). EMA product information (PDF). Downloaded and checked 14 Oct 2026.
  13. CDSCO, Subject Expert Committee (Endocrinology & Metabolism), recommendations of the meeting held on 8 Sep 2026: proposals for "update in Package Insert based on EMA approval" for Novo Nordisk India's semaglutide injection (Wegovy and Poviztra), Ozempic and Rybelsus. CDSCO PDF · archived copy. Checked 14 Oct 2026.

Last checked 14 Oct 2026 · Next review due Jan 2027

How this tool was made. Written by the GLP Guidebook team from the US and EU labels and trial papers above, each opened and checked. We looked for India's own pack inserts on 14 Oct 2026 (the makers' and marketers' Indian websites, CDSCO and web searches) and found none published online. The trials were paid for by the makers of the medicines (Novo Nordisk or Eli Lilly). It's general information, not medical advice, and it doesn't replace the label or your doctor. Talk to a qualified doctor before starting, stopping or changing any medicine. In an emergency in India, call 112. How we write